Repare Therapeutics Inc. (RPTX)
RPTX Stock Price Chart
Explore Repare Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze RPTX price movements and trends.
RPTX Company Profile
Discover essential business fundamentals and corporate details for Repare Therapeutics Inc. (RPTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Jun 2020
Employees
129.00
Website
https://www.reparerx.comCEO
Steve Forte CPA
Description
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
RPTX Financial Timeline
Browse a chronological timeline of Repare Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.49, while revenue estimate is $7.50M.
Earnings released on 8 Aug 2025
EPS came in at -$0.39 surpassing the estimated -$0.56 by +30.36%, while revenue for the quarter reached $250.00K , missing expectations by -85.00%.
Earnings released on 13 May 2025
EPS came in at -$0.71 falling short of the estimated -$0.65 by -9.23%, while revenue for the quarter reached $5.00M , beating expectations by +200.00%.
Earnings released on 3 Mar 2025
EPS came in at -$0.67 surpassing the estimated -$0.77 by +12.99%.
Earnings released on 7 Nov 2024
EPS came in at -$0.81 surpassing the estimated -$0.83 by +2.41%.
Earnings released on 6 Aug 2024
EPS came in at -$0.82 surpassing the estimated -$0.85 by +3.53%, while revenue for the quarter reached $1.07M , missing expectations by -63.13%.
Earnings released on 7 May 2024
EPS came in at $0.30 surpassing the estimated $0.02 by +1.81K%, while revenue for the quarter reached $52.40M , beating expectations by +1.70K%.
Earnings released on 28 Feb 2024
EPS came in at -$0.67 falling short of the estimated -$0.56 by -19.64%, while revenue for the quarter reached $13.05M , beating expectations by +405.70%.
Earnings released on 9 Nov 2023
EPS came in at -$0.45 surpassing the estimated -$0.86 by +47.67%, while revenue for the quarter reached $2.16M , missing expectations by -91.97%.
Earnings released on 9 Aug 2023
EPS came in at -$0.28 surpassing the estimated -$0.83 by +66.27%, while revenue for the quarter reached $30.25M , beating expectations by +293.87%.
Earnings released on 9 May 2023
EPS came in at -$0.83 surpassing the estimated -$0.84 by +1.19%, while revenue for the quarter reached $5.68M , missing expectations by -7.22%.
Earnings released on 28 Feb 2023
EPS came in at -$0.75 falling short of the estimated -$0.73 by -2.74%, while revenue for the quarter reached $18.20M , beating expectations by +87.29%.
Earnings released on 9 Nov 2022
EPS came in at $1.71 surpassing the estimated -$0.89 by +292.13%, while revenue for the quarter reached $112.55M , beating expectations by +5.60K%.
Earnings released on 4 Aug 2022
EPS came in at -$0.91 falling short of the estimated -$0.86 by -5.81%, while revenue for the quarter reached $679.00K , missing expectations by -87.50%.
Earnings released on 5 May 2022
EPS came in at -$0.83 surpassing the estimated -$0.89 by +6.74%, while revenue for the quarter reached $408.00K , missing expectations by -82.65%.
Earnings released on 1 Mar 2022
EPS came in at -$0.70 surpassing the estimated -$0.75 by +6.67%, while revenue for the quarter reached $6.88M , beating expectations by +79.88%.
Earnings released on 10 Nov 2021
EPS came in at -$0.83 falling short of the estimated -$0.70 by -18.57%, while revenue for the quarter reached $278.00K , beating expectations by +22.81%.
Earnings released on 12 Aug 2021
EPS came in at -$0.71 falling short of the estimated -$0.58 by -22.41%, while revenue for the quarter reached $279.00K , meeting expectations.
Earnings released on 13 May 2021
EPS came in at -$0.58 falling short of the estimated -$0.49 by -18.37%, while revenue for the quarter reached $166.00K , beating expectations by +15.91%.
Earnings released on 4 Mar 2021
EPS came in at -$0.41 matching the estimated -$0.41, while revenue for the quarter reached $135.00K .
Earnings released on 11 Nov 2020
EPS came in at -$0.37 surpassing the estimated -$0.41 by +9.76%.
RPTX Stock Performance
Access detailed RPTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.